Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

November 2018

Pharmacy and Therapeutics Committee Meeting Update


At the September 17, 2018 meeting, the Harvard Pilgrim Pharmacy & Therapeutics Committee reviewed the medications below and decided the following:

P&T Committee Review and Decisions

Name

Indication

Decision

Arnuity Ellipta (fluticasone furoate)

Used to control and prevent asthma for patients aged 5 years and older.

• Premium and Value formularies: Moved to preferred brand

• Medicare Advantage Formulary: Remains non-formulary

Stiolto Respimat (tiotropium bromide, olodaterol)

Used to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

• Premium formulary: Moved to preferred brand

• Medicare Advantage formulary: Continued coverage at Tier 3

Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide [TAF])

Used to treat HIV-1 in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed.

• Premium and Value formularies: Moved to preferred brand

• Medicare Advantage formulary: Continued coverage at Tier 5

Genvoya (elvitegravir, cobicistat, emtricitabine, TAF)

Used to treat HIV-1 infection in adults and pediatric patients.

• Premium and Value formularies: Moved to preferred brand

• Medicare Advantage formulary: Continued coverage at Tier 5

Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate TDF)

Used to treat HIV-1 infection in adults and pediatric patients 12 years of age and older.

• Premium and Value formularies: Moved to preferred brand

• Medicare Advantage formulary:
Continued coverage at Tier 5

Descovy (emtricitabine, TAF)

Used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients.

• Premium and Value formularies: Moved to preferred brand

• Medicare Advantage formulary: Continued coverage at Tier 5

Juluca (dolutegravir, rilpivirine)

Used to treat HIV-1 infection in adult patients.

• Premium and Value formularies: Moved to preferred brand

• Medicare Advantage formulary: Continued coverage at Tier 5

Symfi/Symfi Lo (efavirenz, lamivudine, TDF)

Used to treat HIV-1 infection in adult and pediatric patients.

• Premium and Value formularies: Moved to preferred brand

• Medicare Advantage formulary: Continued coverage at Tier 5

Cimduo (Lamivudine, TDF)

Used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult and pediatric patients.

• Premium and Value formularies: Moved to preferred brand

• Medicare Advantage formulary: Continued coverage at Tier 5

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Harvard Pilgrim Regional Network Meeting: Manchester NH Kickoff Event

CLINICIAN CORNER

Prior Authorization for Cervical Spine Procedures

Medicare Advantage: Cardiac Prior Authorization Program

New Emergency Room Cost Sharing Structure for New Hampshire Plans

Updates on Medical Drugs Obtained Through Specialty Pharmacy

Billing Monitored Anesthesia Care Policy for Screening Colonoscopies for Commercial Members

Billing Diagnosis Codes for Preventive Services

Newly Covered Codes for Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI)

Updates to Rituxan Medical Review Criteria

Generic Form of Makena Now Covered

Diabetes Prevention and Management Programs and Resources

New Pharmacy Prior Authorizations for 2019

Pharmacy and Therapeutics Committee Meeting Update

OFFICE ASSISTANT

Update to Reimbursement Process for Observation to Inpatient Transition

Modifier SA for Reporting on Behalf of Non-Physician Practitioners

PUBLICATION INFORMATION

Robert Farias,
Senior Vice President, Corporate Network Strategy

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator